Cautious Outlook on Y-Mabs Therapeutics Due to Delayed Milestones and Early-Stage Pipeline

Analyst Alec Stranahan from Bank of America Securities maintained a Sell rating on Y-Mabs Therapeutics (YMAB – Research Report) and keeping the price target at $3.00.

Alec Stranahan has given his Sell rating due to a combination of factors impacting Y-Mabs Therapeutics. The company’s SADA platform, while showing some initial promise in safety and tumor uptake, requires further optimization to achieve the desired therapeutic index. This need for improvement, particularly in formulation and linker optimization, delays key milestones until the latter half of 2027, which may deter investor confidence in the near term.
Additionally, while the new Proteus radiohapten shows potential for enhanced tumor uptake and interchangeability between isotopes, its benefits are not expected to be realized until further down the line. The company’s pipeline, including assets in lung, women’s, and gastrointestinal cancers, is still in early stages, with significant progress not anticipated for several years. Given these uncertainties and the extended timeline for potential breakthroughs, Stranahan maintains a cautious outlook with a price objective lower than the current trading price.

In another report released on May 13, Morgan Stanley also maintained a Sell rating on the stock with a $7.00 price target.

Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of YMAB in relation to earlier this year.